Global Spinocerebellar Ataxia (SCA) – Pipeline Review, H1 2016 illuminated by new report


“The Report Spinocerebellar Ataxia (SCA) – Pipeline Review, H1 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Global Markets Directs, Spinocerebellar Ataxia (SCA) – Pipeline Review, H1 2016, provides an overview of the Spinocerebellar Ataxia (SCA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at :


– The report provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA)

– The report reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Spinocerebellar Ataxia (SCA) therapeutics and enlists all their major and minor projects

– The report assesses Spinocerebellar Ataxia (SCA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA)

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Spinocerebellar Ataxia (SCA)

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Spinocerebellar Ataxia (SCA) Overview 6

Therapeutics Development 7

Pipeline Products for Spinocerebellar Ataxia (SCA) – Overview 7

Pipeline Products for Spinocerebellar Ataxia (SCA) – Comparative Analysis 8

Spinocerebellar Ataxia (SCA) – Therapeutics under Development by Companies 9

Spinocerebellar Ataxia (SCA) – Therapeutics under Investigation by Universities/Institutes 10

Spinocerebellar Ataxia (SCA) – Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Spinocerebellar Ataxia (SCA) – Products under Development by Companies 14

Spinocerebellar Ataxia (SCA) – Products under Investigation by Universities/Institutes 15

Spinocerebellar Ataxia (SCA) – Companies Involved in Therapeutics Development 16

Baxalta Incorporated 16

Bioblast Pharma Ltd. 17

Kissei Pharmaceutical Co., Ltd. 18

Vybion, Inc. 19

Spinocerebellar Ataxia (SCA) – Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

Antisense RNAi Oligonucleotide to Inhibit Ataxin-7 for Spinocerebellar Ataxia Type 7 – Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

epoetin alfa – Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

immune globulin (human) – Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Follow us on LinkedIn:

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074